Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E ε4 frequency, but no tau gene mutations

被引:64
作者
Fabre, SF [1 ]
Forsell, C
Viitanen, M
Sjögren, M
Wallin, A
Blennow, K
Blomberg, M
Andersen, C
Wahlund, LO
Lannfelt, L
机构
[1] Karolinska Inst, Dept NEUROTEC, Geriatr Med Sect, KFC,Novum, S-14186 Huddinge, Sweden
[2] Sahlgrens Univ Hosp, Inst Clin Neurosci, S-43180 Molndal, Sweden
[3] Swedish Med Res Council, Stockholm, Sweden
关键词
frontotemporal dementia; tau; cerebrospinal fluid; apolipoprotein E; polymorphisms;
D O I
10.1006/exnr.2000.7613
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Frontotemporal dementia (FTD) belongs to a group of neurodegenerative disorders known as tauopathies, characterized by intracellular aggregation of hyperphosphorylated tau protein in the brain. Some tauopathies, like Alzheimer's disease (AD), consistently show increased levels of tau protein in cerebrospinal fluid (CSF), However, similar studies in FTD populations have shown variable results, although mutations in the tau gene are identified as causes of disease in certain FTD families. In the present study, a Swedish clinic-based FTD population was investigated with respect to CSF tan levels, apolipoprotein E (APOE) genotype distribution and occurrence of mutations in the tau gene. CSF tau levels were significantly increased among FTD patients (534 +/- 235 pg tau/ml, P < 0.001) (n = 47) compared to controls (316 <plus/minus> 137 pg tau/ml) (n = 51), Furthermore, a strong increase in the APOE epsilon4 allele frequency was found in the FTD population, as 52% were epsilon4 carriers, compared to 21% of the controls. However, no mutations in the tau gene were identified. These findings support the present notion of a common pathogenic pathway in the disease processes for several tauopathies, with both APOE epsilon4 and CSF tau being a pathological link between the different disorders. Furthermore, we conclude that mutations in the tau gene are a rare cause of FTD, (C) 2001 Academic Press.
引用
收藏
页码:413 / 418
页数:6
相关论文
共 47 条
[1]
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].
Andreasen, N ;
Vanmechelen, E ;
Van de Voorde, A ;
Davidsson, P ;
Hesse, C ;
Tarvonen, S ;
Räihä, I ;
Sourander, L ;
Winblad, B ;
Blennow, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305
[2]
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology [J].
Arai, H ;
Morikawa, Y ;
Higuchi, M ;
Matsui, T ;
Clark, CM ;
Miura, M ;
Machida, N ;
Lee, VMY ;
Trojanowski, JQ ;
Sasaki, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) :262-264
[3]
Association of an extended haplotype in the tau gene with progressive supranuclear palsy [J].
Baker, M ;
Litvan, I ;
Houlden, H ;
Adamson, J ;
Dickson, D ;
Perez-Tur, J ;
Hardy, J ;
Lynch, T ;
Bigio, E ;
Hutton, M .
HUMAN MOLECULAR GENETICS, 1999, 8 (04) :711-715
[4]
Bancher C, 1998, J NEURAL TRANSM-SUPP, P185
[5]
Direct genetic evidence for involvement of tau in progressive supranuclear palsy [J].
Bennett, P ;
Bonifati, V ;
Bonuccelli, U ;
Colosimo, C ;
De Mari, M ;
Fabbrini, G ;
Marconi, R ;
Meco, G ;
Nicholl, DJ ;
Stocchi, F ;
Vanacore, N ;
Vieregge, P ;
Williams, AC .
NEUROLOGY, 1998, 51 (04) :982-985
[6]
tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[7]
BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416
[8]
BUEE L, 1999, BRAIN PATHOL, V9
[9]
A polymorphism in the tau gene associated with risk for Alzheimer's disease [J].
Bullido, MJ ;
Aldudo, J ;
Frank, A ;
Coria, F ;
Avila, J ;
Valdivieso, F .
NEUROSCIENCE LETTERS, 2000, 278 (1-2) :49-52
[10]
Inheritance of frontotemporal dementia [J].
Chow, TW ;
Miller, BL ;
Hayashi, VN ;
Geschwind, DH .
ARCHIVES OF NEUROLOGY, 1999, 56 (07) :817-822